< Back to previous page
Researcher
Paul Declerck
- Disciplines:Laboratory medicine, Regenerative medicine, Other basic sciences, Other health sciences, Other medical and health sciences, Medical biotechnology, Drug discovery and development, Pharmaceutics
Affiliations
- Therapeutic and Diagnostic Antibodies (Division)
Responsible
From1 Apr 2013 → Today - Therapeutic and Diagnostic Antibodies (Division)
Member
From1 Apr 2013 → Today
Projects
1 - 10 of 33
- An integrated platform for the identification, isolation and characterization of human clock antibodies.From1 Jul 2021 → TodayFunding: Department Coordination
- VyCAP single cell isolation platform for high-quality single-cell analysisFrom1 Jan 2021 → 31 Dec 2022Funding: BOF - scientific equipment program
- A Pharmacometrics Approach to Improve Dose Individualisation Methods of Biologicals in Patients with Chronic Inflammatory DiseasesFrom13 Oct 2020 → TodayFunding: FWO fellowships
- Development and streamlining a validation and implementation workflow for model-informed precision dosing for biologicals and antimicrobialsFrom1 Oct 2020 → 30 Sep 2022Funding: IOF - technology validation in lab
- Advancing DNA-based antibody therapeutics through evaluation and characterization of in vivo expression, complex antibody formats, and delivery formulationsFrom1 Sep 2020 → TodayFunding: FWO fellowships, Foundations, funds and other with scientific goal
- Crystallographic facility for target-based drug designFrom1 May 2020 → TodayFunding: FWO International research infrastructure
- Translational research related to Corona-Covid 19From1 Apr 2020 → 31 Mar 2021Funding: IOF - technology validation in lab, BOF - various
- Anti-tau intrabodies for the treatment of Alzheimer’s diseaseFrom1 Feb 2020 → TodayFunding: Baekeland
- Extracellular Vesicle Tracking using surface proteins and Resonance Assays to detect breast Cancer in Early stage (EV-TRACE)From1 Jan 2020 → TodayFunding: FWO Strategic Basic Research (SBO)
- An on-chip single B cell mining platform for rapid development of fully human therapeutic antibodies and for immunoprofiling human antibody responsesFrom1 Oct 2019 → 30 Sep 2022Funding: IOF - technology validation in lab
Publications
1 - 10 of 150
- Higher Drug Exposure During the First 24 Weeks of Ustekinumab Treatment Is Associated With Endoscopic Remission in Crohn's Disease.(2023)
Authors: Nathalie Van den Berghe, Bram Verstockt, Séverine Vermeire, Debby Thomas, Paul Declerck
Pages: 838 - 840.e2 - FLUIDOT: a Modular Microfluidic Platform for Single-Cell Study and Retrieval, with Applications in Drug Tolerance Screening and Antibody Mining(2023)
Authors: Jolien Breukers, Karen Ven, Iene Rutten, Maya Imbrechts, Julie Van Lent, Winnie Kerstens, Samuel Noppen, Dominique Schols, Hendrik Jan Thibaut, Karen Vanhoorelbeke, et al.
- Identification of a Phage Display-Derived Peptide Interacting with the N-Terminal Region of Factor VII Activating Protease (FSAP) Enables Characterization of Zymogen Activation(2022)
Authors: Paul Declerck
Pages: 2631 - 2642 - Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking(2022)
Authors: Liese Barbier, Steven Simoens, Paul Declerck, Arnold Vulto, Isabelle Huys
- Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis(2022)
Authors: Rani Soenen, Zhigang Wang, Erwin Dreesen, Paul Declerck, Debby Thomas
Pages: 1324 - 1336 - Intratumoral gene transfer of immunomodulatory antibody combinations: a preclinical proof-of-concept study(2021)
Authors: Liesl Jacobs, Paul Declerck, Adrian Liston, Kevin Hollevoet
- Sustainable biosimilar competition: clinical, regulatory and policy insights(2021)
Authors: Liese Barbier, Isabelle Huys, Paul Declerck, Steven Simoens
- The value of therapeutic drug monitoring to guide treatment optimisation of biologicals in patients with chronic inflammatory diseases: focus on vedolizumab and ustekinumab(2021)
Authors: Nathalie Van den Berghe, Paul Declerck, Séverine Vermeire, Debby Thomas
- Intratumoral DNA-based delivery of checkpoint-inhibiting antibodies and interleukin 12 triggers T cell infiltration and anti-tumor response(2021)
Authors: Liesl Jacobs, Lidia Yshii, Steffie Junius, Nick Geukens, Adrian Liston, Paul Declerck
Pages: 984 - 992 - UNLOCKING THE POTENTIAL OF PLASMID-BASED ANTIBODY GENE TRANSFER(2021)
Authors: Giles Vermeire, Paul Declerck, Kevin Hollevoet
Patents
1 - 3 of 3
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)
- Dual targeting of tafi and pai-1 (Inventor)
Linked dataset
1 - 1 of 1